The "New" Place of LEVETIRACETAM in the Management of Status Epilepticus in Children
The "New" Place of LEVETIRACETAM in the Management of Status Epilepticus in Children: Multicenter Retrospective Study on 151 Children Over Three Months Old
University Hospital, Strasbourg, France
151 participants
Nov 16, 2023
OBSERVATIONAL
Conditions
Summary
Status epilepticus is the leading neurological emergency in children, with mortality 2-7% and significant morbidity (10-20%). It is defined as the occurrence of a crisis lasting more than 5 minutes and requiring the implementation of treatment to stop it and thus limit the immediate and long-term consequences. The research hypothesis is that LEVETIRACETAM is non-inferior to PHENYTOIN in terms of cessation and absence of recurrence of status epilepticus, with better clinical tolerance in children from 3 months to 17 years old, with or without epileptic disease, with or without a history of status epilepticus
Eligibility
Inclusion Criteria4
- Minor patient aged 3 months to 17 years
- nd line treatment with LEVETIRACETAM or PHENYTOIN after failure of benzodiazepines
- Supported in one of the participating centers during the period from November 1, 2019 to May 31, 2023
- Subject or parents who have not expressed, after information, their opposition to the reuse of their data for the purposes of this research.
Exclusion Criteria1
- Patient or parents having expressed their opposition to participating in the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06498362